Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex

被引:1167
作者
Le Blanc, K
Tammik, L
Sundberg, B
Haynesworth, SE
Ringdén, O
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Haematol, Div Clin Immunol, SE-14186 Stockholm, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Ctr Allogeneic Stem Cell Transplantat, SE-14186 Stockholm, Sweden
[3] Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA
关键词
D O I
10.1046/j.1365-3083.2003.01176.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We aimed to study the effects of mesenchymal stem cells (MSCs) on alloreactivity and effects of T-cell activation on human peripheral blood lymphocytes (PBLs) in vitro . MSCs were expanded from the bone marrow of healthy subjects. MSCs isolated from second to third passage were positive for CD166, CD105, CD44, CD29, SH-3 and SH-4, but negative for CD34 and CD45. MSCs cultured in osteogenic, adipogenic or chondrogenic media differentiated, respectively, into osteocytes, adipocytes or chondrocytes. MSC added to PBL cultures had various effects, ranging from slight inhibition to stimulation of DNA synthesis. The stimulation index (SI = (PBL + MSC)/PBL) varied between 0.2 and 7.3. The SI was not affected by the MSC dose or by the addition of allogeneic or autologous MSCs to the lymphocytes. Suppression of proliferative activity was observed in all experiments after the addition of 10,000-40,000 MSCs to mixed lymphocyte cultures (MLCs). Lymphocyte proliferation was 10-90%, compared with a control MLC run in parallel without MSCs. In contrast, the addition of fewer MSCs (10-1000 cells) led to a less consistent suppression or a marked lymphocyte proliferation in several experiments, ranging from 40 to 190% of the maximal lymphocyte proliferation in control MLCs. The ability to inhibit or stimulate T-cell alloresponses appeared to be independent of the major histocompatibility complex, as results were similar using 'third party' MSCs or MSCs that were autologous to the responder or stimulating PBLs. The strongest inhibitory effect was seen if MSCs were added at the beginning of the 6 day culture, and the effect declined if MSCs were added on day 3 or 5. Marked inhibitory effects of allogeneic and autologous MSCs (15,000) were also noted after mitogenic lymphocyte stimulation by phytohaemagglutinin (median lymphocyte proliferation of 30% of controls), Concanavalin A (56%) and protein A (65%). Little, if any, inhibition occurred after stimulation with pokeweed mitogen. Low numbers of MSCs (150 cells) were unable to inhibit mitogen-induced T-cell responses. MSCs have significant immune modulatory effects on MLCs and after mitogenic stimulation of PBL. High numbers of MSCs suppress alloreactive T cells, whereas very low numbers clearly stimulated lymphocyte proliferation in some experiments. The effect of a larger number of MSCs on MLCs seems more dependent on cell dose than histocompatibility and could result from an 'overload' of a stimulatory mechanism.
引用
收藏
页码:11 / 20
页数:10
相关论文
共 38 条
  • [1] Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation
    Almeida-Porada, G
    Porada, CD
    Tran, N
    Zanjani, ED
    [J]. BLOOD, 2000, 95 (11) : 3620 - 3627
  • [2] ANKLESARIA P, 1989, BLOOD, V74, P1144
  • [3] Archambault MP, 2000, BLOOD, V96, p762A
  • [4] α4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo
    Arroyo, AG
    Yang, JT
    Rayburn, H
    Hynes, RO
    [J]. IMMUNITY, 1999, 11 (05) : 555 - 566
  • [5] Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo
    Bartholomew, A
    Patil, S
    Mackay, A
    Nelson, M
    Buyaner, D
    Hardy, W
    Mosca, J
    Sturgeon, C
    Siatskas, M
    Mahmud, N
    Ferrer, K
    Deans, R
    Moseley, A
    Hoffman, R
    Devine, SM
    [J]. HUMAN GENE THERAPY, 2001, 12 (12) : 1527 - 1541
  • [6] Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo
    Bartholomew, A
    Sturgeon, C
    Siatskas, M
    Ferrer, K
    McIntosh, K
    Patil, S
    Hardy, W
    Devine, S
    Ucker, D
    Deans, R
    Moseley, A
    Hoffman, R
    [J]. EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) : 42 - 48
  • [7] Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO
  • [8] 2-F
  • [9] Mesenchymal stem cells: Biology and potential clinical uses
    Deans, RJ
    Moseley, AB
    [J]. EXPERIMENTAL HEMATOLOGY, 2000, 28 (08) : 875 - 884
  • [10] Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion
    Devine, SM
    Bartholomew, AM
    Mahmud, N
    Nelson, M
    Patil, S
    Hardy, W
    Sturgeon, C
    Hewett, T
    Chung, T
    Stock, W
    Sher, D
    Weissman, S
    Ferrer, K
    Mosca, J
    Deans, R
    Moseley, A
    Hoffman, R
    [J]. EXPERIMENTAL HEMATOLOGY, 2001, 29 (02) : 244 - 255